Discordance in Genotypic and Phenotypic Drug Susceptibility Results: Time to Reconsider Critical Concentration of Rifampicin

Overview

Journal Microbiol Spectr

Date 2025 Feb 4

PMID 39902977

Authors

Arti Shrivas

Sarman Singh

Jitendra Singh

Prem Shankar

Payal Soni

Syed Beenish Rufai

Anand Maurya

Shashank Purwar

Affiliations

Soon will be listed here.

Abstract

Importance: Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide, killing millions every year. The emergence of multidrug-resistant and extensively drug-resistant TB forms poses a challenge to the TB control programs. In the past few decades, several molecular tests for rapid detection and drug resistance determination have been developed. But these can miss the genetic mutations that confer low-level resistance to rifampicin (RIF), a critical constituent for treating drug-susceptible TB. On the other hand, for the phenotypic methods, a cutoff value is fixed, known as critical concentration (CC). The current WHO-endorsed CC for rifampicin is 1.0 μg/mL in liquid culture for confirmation of drug resistance; because of that in this system too, low-level RIF resistance may not be correctly identified. Therefore, it is important that either the CC for phenotypic methods is lowered or the specific mutations are included in the molecular tests. This study provides important insights in that direction.

References

van Ingen J, Aarnoutse R, de Vries G, Boeree M, van Soolingen D . Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. Int J Tuberc Lung Dis. 2011; 15(7):990-2. DOI: 10.5588/ijtld.10.0127. View

Singh J, Sankar M, Kumar P, Couvin D, Rastogi N, Singh S . Genetic diversity and drug susceptibility profile of Mycobacterium tuberculosis isolated from different regions of India. J Infect. 2015; 71(2):207-19. DOI: 10.1016/j.jinf.2015.04.028. View

Sankar M, Singh J, Diana S, Singh S . Molecular characterization of Mycobacterium tuberculosis isolates from North Indian patients with extrapulmonary tuberculosis. Tuberculosis (Edinb). 2012; 93(1):75-83. DOI: 10.1016/j.tube.2012.10.005. View

Shah N, Grace Lin S, Barry P, Cheng Y, Schecter G, Desmond E . Clinical Impact on Tuberculosis Treatment Outcomes of Discordance Between Molecular and Growth-Based Assays for Rifampin Resistance, California 2003-2013. Open Forum Infect Dis. 2016; 3(3):ofw150. PMC: 5047429. DOI: 10.1093/ofid/ofw150. View

Andre E, Goeminne L, Colmant A, Beckert P, Niemann S, Delmee M . Novel rapid PCR for the detection of Ile491Phe rpoB mutation of Mycobacterium tuberculosis, a rifampicin-resistance-conferring mutation undetected by commercial assays. Clin Microbiol Infect. 2016; 23(4):267.e5-267.e7. DOI: 10.1016/j.cmi.2016.12.009. View

Gopie F, Commiesie E, Baldi S, Kamst M, Kaur D, de Lange W . Should treatment of low-level rifampicin mono-resistant tuberculosis be different?. J Clin Tuberc Other Mycobact Dis. 2021; 23:100222. PMC: 7869001. DOI: 10.1016/j.jctube.2021.100222. View

Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston M . Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993; 341(8846):647-50. DOI: 10.1016/0140-6736(93)90417-f. View

Wang W, Liu R, Yao C, Huo F, Shang Y, Zhang X . Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with Disputed Mutations and Discordant Susceptibility Phenotypes. Microbiol Spectr. 2022; 10(1):e0208721. PMC: 8809345. DOI: 10.1128/spectrum.02087-21. View

Mitchison D . Basic mechanisms of chemotherapy. Chest. 1979; 76(6 Suppl):771-81. DOI: 10.1378/chest.76.6_supplement.771. View

10.

van Ingen J, Rahim Z, Mulder A, Boeree M, Simeone R, Brosch R . Characterization of Mycobacterium orygis as M. tuberculosis complex subspecies. Emerg Infect Dis. 2012; 18(4):653-5. PMC: 3309669. DOI: 10.3201/eid1804.110888. View

11.

Torrea G, Ng K, Van Deun A, Andre E, Kaisergruber J, Ssengooba W . Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance. Sci Rep. 2019; 9(1):11826. PMC: 6694172. DOI: 10.1038/s41598-019-48401-z. View

12.

Rando-Segura A, Aznar M, Moreno M, Soley M, Igual E, Bocanegra Garcia C . Molecular characterization of rpoB gene mutations in isolates from tuberculosis patients in Cubal, Republic of Angola. BMC Infect Dis. 2021; 21(1):1056. PMC: 8507306. DOI: 10.1186/s12879-021-06763-8. View

13.

Schon T, Jureen P, Chryssanthou E, Giske C, Kahlmeter G, Hoffner S . Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?. J Antimicrob Chemother. 2013; 68(9):2074-7. DOI: 10.1093/jac/dkt150. View

14.

Andres S, Hillemann D, Rusch-Gerdes S, Richter E . Occurrence of rpoB mutations in isoniazid-resistant but rifampin-susceptible Mycobacterium tuberculosis isolates from Germany. Antimicrob Agents Chemother. 2013; 58(1):590-2. PMC: 3910775. DOI: 10.1128/AAC.01752-13. View

15.

Ho J, Jelfs P, Sintchencko V . Phenotypically occult multidrug-resistant Mycobacterium tuberculosis: dilemmas in diagnosis and treatment. J Antimicrob Chemother. 2013; 68(12):2915-20. DOI: 10.1093/jac/dkt284. View

16.

Singh S, Kumar P, Sharma S, Mumbowa F, Martin A, Durier N . Rapid Identification and Drug Susceptibility Testing of Mycobacterium tuberculosis: Standard Operating Procedure for Non-Commercial Assays: Part 3: Colorimetric Redox Indicator Assay v1.3.12. J Lab Physicians. 2013; 4(2):120-6. PMC: 3574496. DOI: 10.4103/0974-2727.105594. View

17.

Berrada Z, Lin S, Rodwell T, Nguyen D, Schecter G, Pham L . Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex. Diagn Microbiol Infect Dis. 2016; 85(2):177-81. PMC: 4873381. DOI: 10.1016/j.diagmicrobio.2016.01.019. View

18.

Ramaswamy S, Musser J . Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 2000; 79(1):3-29. DOI: 10.1054/tuld.1998.0002. View

19.

Yip C, Leung K, Wong D, Cheung D, Chu M, Tang H . Denaturing HPLC for high-throughput screening of rifampicin-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis. 2006; 10(6):625-30. View

20.

Shea J, Halse T, Kohlerschmidt D, Lapierre P, Modestil H, Kearns C . Low-Level Rifampin Resistance and Mutations in Mycobacterium tuberculosis: an Analysis of Whole-Genome Sequencing and Drug Susceptibility Test Data in New York. J Clin Microbiol. 2020; 59(4). PMC: 8579749. DOI: 10.1128/JCM.01885-20. View